至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA

J Nanobiotechnology. 2021-01; 
Long Zhang, Chaofeng Mu, Tinghong Zhang, Dejun Yang, Chenou Wang, Qiong Chen, Lin Tang, Luhui Fan, Cong Liu, Jianliang Shen, Huaqiong Li
Products/Services Used Details Operation
Custom DNA/RNA Oligos The RNA oligonucleotides were synthesized chemically (Genscript) then mixed in an equal molar ratio in TMS buffer and annealed to generate uniform NPs Get A Quote

摘要

background: To date, triple-negative breast cancer (TNBC) treatment options are limited because of the loss of target receptors and, as a result, are only managed with chemotherapy. What is worse is that TNBC is frequently developing resistance to chemotherapy. By using small interfering RNA (siRNA)-based therapeutics, our recent work demonstrated X-box-binding protein 1 (XBP1) was linked to human epidermal growth factor receptor 2 positive (HER2+) breast cancer development and chemoresistance. Given the instability, off-target effects, net negative charge, and hydrophobicity of siRNA in vivo utilization and clinical transformation, its use in treatment is hampered. Thus, the development of a siRNA-based drug d... More

关键词

Chemoresistance, RNA nanoparticles, TNBC, XBP1, siRNA